Recent investigations have centered on the overlap of GLP|GIP|glucagon receptor agonist therapies and DA communication. While GIP agonists are commonly employed for treating type 2 T2DM, their emerging effects on motivation circuits, specifically mediated by DA networks, are receiving considerable interest. This paper provides a summary assessment